Abstract：
BACKGROUND: Zuranolone, an oral version of allopregnanolone and neurosteroid, is a novel drug for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
OBJECTIVE: The purpose of this systematic review and meta-analysis was to assess the efficacy of zuranolone in the treatment of MDD and PPD.
METHODS: A systematic search was conducted using EBSCOhost to simultaneously search Academic Search Premier, APA PsycArticles, APA PsycInfo, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, CINAHL Ultimate, and MEDLINE with Full Text. Two independent reviewers screened the articles and completed a full-text review using Covidence. The quality of each study was assessed using the Cochrane Risk of Bias tool for randomized trials (RoB 2). A meta-analysis was then conducted using Review Manager (RevMan v5.4) software.
RESULTS: The initial search yielded 127 results, with 6 articles fitting our inclusion and exclusion criteria. All 6 studies, comprising 1707 participants, had an overall low risk of bias. There was a significant decrease in HAM-D scores for MDD at 15 days versus placebo (MD - 2.40, 95% CI - 3.07 to - 1.63; p < .001). When pooling data for PDD, there was an overall significant decrease in HAM-D scores at 15 days versus placebo (MD - 4.06, 95% CI - 4.25 to - 3.87; p < .001).
CONCLUSIONS: The results suggest that zuranolone can improve symptoms of PPD at 15 days; however, results were not clinically significant for MDD. Future research is needed to evaluate the long-term efficacy of zuranolone in PPD and the treatment efficacy in MDD.
OBJECTIVE: The purpose of this systematic review and meta-analysis was to assess the efficacy of zuranolone in the treatment of MDD and PPD.
METHODS: A systematic search was conducted using EBSCOhost to simultaneously search Academic Search Premier, APA PsycArticles, APA PsycInfo, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, CINAHL Ultimate, and MEDLINE with Full Text. Two independent reviewers screened the articles and completed a full-text review using Covidence. The quality of each study was assessed using the Cochrane Risk of Bias tool for randomized trials (RoB 2). A meta-analysis was then conducted using Review Manager (RevMan v5.4) software.
RESULTS: The initial search yielded 127 results, with 6 articles fitting our inclusion and exclusion criteria. All 6 studies, comprising 1707 participants, had an overall low risk of bias. There was a significant decrease in HAM-D scores for MDD at 15 days versus placebo (MD - 2.40, 95% CI - 3.07 to - 1.63; p < .001). When pooling data for PDD, there was an overall significant decrease in HAM-D scores at 15 days versus placebo (MD - 4.06, 95% CI - 4.25 to - 3.87; p < .001).
CONCLUSIONS: The results suggest that zuranolone can improve symptoms of PPD at 15 days; however, results were not clinically significant for MDD. Future research is needed to evaluate the long-term efficacy of zuranolone in PPD and the treatment efficacy in MDD.
摘要：
背景：Zuranolone，口服别孕烷醇酮和神经类固醇，是一种治疗重度抑郁症（MDD）和产后抑郁症（PPD）的新药。
目的：本系统综述和荟萃分析的目的是评估Zuranolone治疗MDD和PPD的疗效。
方法：使用EBSCOhost进行了系统搜索，以同时搜索学术搜索Premier，APAPsycarticles,APAPsycInfo，Cochrane中央控制试验登记册,Cochrane系统评价数据库，CINAHLUltimate,和MEDLINE与全文。两名独立审稿人对文章进行了筛选，并使用Covidence完成了全文审查。使用Cochrane偏差风险工具进行随机试验（RoB2）评估每个研究的质量。然后使用ReviewManager(RevManv5.4)软件进行荟萃分析。
结果：最初的搜索产生了127个结果，有6篇文章符合我们的纳入和排除标准。所有6项研究，由1707名参与者组成，总体上有较低的偏倚风险。与安慰剂相比，15天时MDD的HAM-D评分显着降低（MD-2.40，95％CI-3.07至-1.63；p<.001）。当汇集用于PDD的数据时，与安慰剂组相比,15天时HAM-D评分总体显著下降(MD-4.06,95%CI-4.25~-3.87;p<.001).
结论：结果表明，在15天，唑兰隆可以改善PPD的症状；然而，MDD的结果无临床意义.需要进一步的研究来评估Zuranolone在PPD中的长期疗效以及在MDD中的治疗效果。
目的：本系统综述和荟萃分析的目的是评估Zuranolone治疗MDD和PPD的疗效。
方法：使用EBSCOhost进行了系统搜索，以同时搜索学术搜索Premier，APAPsycarticles,APAPsycInfo，Cochrane中央控制试验登记册,Cochrane系统评价数据库，CINAHLUltimate,和MEDLINE与全文。两名独立审稿人对文章进行了筛选，并使用Covidence完成了全文审查。使用Cochrane偏差风险工具进行随机试验（RoB2）评估每个研究的质量。然后使用ReviewManager(RevManv5.4)软件进行荟萃分析。
结果：最初的搜索产生了127个结果，有6篇文章符合我们的纳入和排除标准。所有6项研究，由1707名参与者组成，总体上有较低的偏倚风险。与安慰剂相比，15天时MDD的HAM-D评分显着降低（MD-2.40，95％CI-3.07至-1.63；p<.001）。当汇集用于PDD的数据时，与安慰剂组相比,15天时HAM-D评分总体显著下降(MD-4.06,95%CI-4.25~-3.87;p<.001).
结论：结果表明，在15天，唑兰隆可以改善PPD的症状；然而，MDD的结果无临床意义.需要进一步的研究来评估Zuranolone在PPD中的长期疗效以及在MDD中的治疗效果。
